Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H ( (HK:1858) ) has issued an announcement.
Beijing Chunlizhengda Medical Instruments Co., Ltd. reported strong preliminary results for 2025, driven by synergies between its domestic and international operations in the orthopedic medical device market. The company emphasized improved operational management and resource allocation as key drivers of efficiency and profitability.
Total operating revenue rose 29.52% year-on-year to RMB1.04 billion, while net profit attributable to shareholders more than doubled, jumping 117.72% to RMB272.1 million. Total assets grew 5.58% and net assets per share increased 5.86%, underscoring a solid strengthening of the balance sheet and suggesting enhanced returns and resilience for investors despite the data being unaudited and subject to final confirmation.
The most recent analyst rating on (HK:1858) stock is a Buy with a HK$16.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
More about Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
Beijing Chunlizhengda Medical Instruments Co., Ltd. is a PRC-based medical device manufacturer focused on orthopedic implants and related surgical instruments, serving both domestic and overseas markets. Listed in Hong Kong, the group has been leveraging centralized procurement policies and expanding international operations to build a more balanced China–overseas revenue mix.
Average Trading Volume: 874,201
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.69B
For a thorough assessment of 1858 stock, go to TipRanks’ Stock Analysis page.